Board of Directors


Paul A. Brooke – Chairman of the Board of Directors
Mr. Brooke has served as a member of our Board of Directors since June 2018 and as Chairman of the Board of Directors since July 2018. He was a founder and managing partner of venBio, LLC, a pharmaceutical investment company, from which he retired at the end of 2016. Mr. Brooke was Chairman of the Board of Directors of Alsius Corporation, a medical device company, from June 2007 through its sale in May 2009, and was the Chairman and Chief Executive Officer of a predecessor company from April 2005 to June 2007. Mr. Brooke has been the Managing Member of PMSV Holdings, LLC, a private investment firm, since 1993. He also served as a Senior Advisor to Morgan Stanley & Co. Incorporated from April 2000 to December 2009, and was a Venture Partner at MPM Capital, a venture capital firm specializing in the healthcare industry, from 1997 through 2006. From April 1999 through May 2000, Mr. Brooke served as a Managing Director at Tiger Management LLC. He was a Managing Director and the Global Head of Healthcare Research and Strategy at Morgan Stanley & Co. from 1983 to April 1999. Mr. Brooke is also a director of several privately held companies. Mr. Brooke was selected to serve on our Board of Directors because he has leadership experience and insight into the operations, challenges and complex issues facing healthcare companies gained from his experience as head of healthcare research at a major investment bank and as an investor.

Lindsay A. Rosenwald, M.D. – Director
Dr. Rosenwald has almost 25 years of experience as a biotechnology entrepreneur, including the founding and recapitalization of numerous public and private biotechnology and life sciences companies. In addition to serving as a director of Caelum, Dr. Rosenwald is Chairman, President and CEO of Fortress Biotech, Caelum’s parent company. Dr. Rosenwald is also a Co-Portfolio Manager and Partner at Opus Point Partners Management, LLC, a life-science focused asset management firm. Before moving into his current positions, Dr. Rosenwald served as Chairman of Paramount BioCapital, Inc. Dr. Rosenwald received an M.D. from Temple University School of Medicine and a B.S. in finance from Pennsylvania State University.

Michael Spector – President and Chief Executive Officer and Director
Mr. Spector was named President and Chief Executive Officer in January 2017 and has served on our board of directors since March 2017. He joined Caelum from Fortress Biotech, where he leveraged more than 25 years of biotechnology experience to identify emerging and innovative technologies to launch as new biotech and specialty pharmaceutical companies. Prior to Fortress, Mr. Spector served as Senior Vice President, Global Commercial Operations at Iroko Pharmaceuticals. Earlier in his career, he spent 15 years at GlaxoSmithKline in multiple senior management positions, including Vice President and General Manager of GlaxoSmithKline South Africa, where he led the overall business strategy and was elected to run the South African Pharmaceutical Manufacturers Association. Mr. Spector is also a founding member of Windhoek Healthcare, where he launched two specialty pharmaceutical companies: Laurel Pharmaceuticals and North Creek Pharmaceuticals. Mr. Spector holds an M.B.A. from Rider University in Lawrenceville, N.J., where he serves on the Business and Scientific Advisory Boards, and a B.S. in biology from the University of Pittsburgh. He

Rodney H. Falk, M.D., FACC – Director
Dr. Falk joined our Board of Directors in April 2019. A world-renowned expert in cardiac amyloidosis, Dr. Falk is the director of the Amyloidosis Program and a cardiovascular medicine specialist at Brigham and Women’s Hospital (BWH). He is also an associate professor of medicine at Harvard Medical School.

Dr. Falk received his medical degree from the University of Birmingham Medical School in the United Kingdom.  After initial training in the UK, he completed a cardiology fellowship at  Brigham and Women’s Hospital and Harvard School of Public Health. Dr. Falk is board certified in internal medicine and cardiovascular disease.

The author of over 150 peer-reviewed publications, and contributor to several major cardiology textbooks, Dr. Falk is a clinician-scientist whose research focuses on understanding cardiac amyloidosis and treatment of this rare disease. His research has been supported by the National Institutes of Health.

Suzanne Lentzsch, M.D., Ph.D. – Director
Dr. Lentzsch joined our Board of Directors in April 2019 and has over 26 years of experience in the field of medicine.  Dr. Lentzsch is a Professor of Medicine and the Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York. She received her medical and doctorate degrees from Humboldt University/The Charité in Berlin, Germany. Her postdoctoral training included residency and fellowship at Humboldt University and a research fellowship in the Jerome Lipper Multiple Myeloma Center (under the mentorship of Dr. Kenneth Anderson of the Dana-Farber Cancer Institute) studying the mechanism of action of thalidomide and its derivatives in multiple myeloma. Before joining the faculty at Columbia University, Dr. Lentzsch was the Clinical Director of the Multiple Myeloma Program at the University of Pittsburgh and University of Pittsburgh Cancer Institute.

Dr. Lentzsch is an active translational researcher, serving as principal investigator for many clinical trials, including investigator-initiated studies for multiple myeloma and AL amyloidosis. Additionally, her translational laboratory research work provided critical insights to understanding the mechanism of action of multiple myeloma bone disease and anti-amyloid treatment strategies.

Dr. Lentzsch’s research is funded by multiple RO1s and awards from, e.g., the Pennsylvania Department of Health, the German Cancer Foundation, the Leukemia and Lymphoma Society, the Multiple Myeloma Research Foundation, Cancer Research Institute, Emerson Collect Fund, and the International Myeloma Society. As a frequent lecturer, Dr. Lentzsch regularly presents at annual meetings of the Society of Hematologic Oncology (SOHO), American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), of which she is also a member. Dr. Lentzsch has published over 100 original articles, editorials, chapters, many as the lead or senior author, in high-impact journals such as JCI, JCO, Blood, Cancer Research, and Leukemia.

Dr. Lentzsch chairs multiple Data Safety Monitoring Committees, is a member of the NCI Myeloma Steering Committee, the SWOG Myeloma Working Group, and co-chairs the Career Development Committee of the International Myeloma Society (IMS).

Harlan Weisman, M.D. – Director
Dr. Weisman joined our Board of Directors in December 2018.  He has 30 years experience as a senior healthcare executive responsible for the discovery, development, regulatory approval and launch of pharmaceutical, biopharmaceutical, medical device and diagnostic products. He is currently Managing Director of And-One Consulting, LLC, advising medical product companies, investment firms, and government and non-government healthcare organizations in formulating and implementing strategies for driving innovation in healthcare products and services. Dr. Weisman is also on the Board of Directors of ControlRad, Inc., 3DBio Therapeutics and TFF Pharmaceuticals.  He is a Senior Advisor to CRG, a healthcare investment firm and a Venture Advisor to the Israel Biotech Fund. He is on advisory committees to the Johns Hopkins University Institute for Basic Biomedical Sciences, Memorial Sloan Kettering Cancer Center and BioMotiv, a medical product accelerator company.

Previously, Dr. Weisman was Chairman and CEO of Coronado Biosciences, Inc., a biopharmaceutical company that was developing novel immunotherapies for autoimmune diseases and cancer. Prior to Coronado, he was a senior executive at Johnson & Johnson for over 20 years. Dr. Weisman was the Chief Science and Technology Officer of the J&J Medical Devices and Diagnostics Group from 2006-2012. He served on the Board of Directors of J&J Development Corporation (JJDC) and as Chairman of the J&J Worldwide R&D Council. Preceding these roles, he was Company Group Chairman, J&J Pharmaceutical Research & Development, and before this he was President of Centocor R&D. Prior to joining industry, Dr. Weisman was Assistant Professor of Medicine at Johns Hopkins University School of Medicine and Consultant Cardiologist at Johns Hopkins Hospital. He has a B.A. from the University of Maryland and M.D. from the University of Maryland School of Medicine. Dr. Weisman completed an Internal Medicine residency at Mount Sinai Hospital in New York and a fellowship in cardiovascular disease at Johns Hopkins Medical Institutions. Dr. Weisman has authored more than 100 articles and book chapters about cardiovascular disease, medical product development, healthcare policy and organizational development.

Martine Zimmerman, Pharm.D. – Director
Dr. Zimmerman has served on our Board since March 2019.  Dr. Zimmerman is the Senior Vice President and Head of Global Regulatory Affairs at Alexion Pharmaceuticals. Based in Zurich, she has over 20 years of combined R&D and global regulatory strategy experience. She joined Alexion in 2009 and since then has been dedicated to the registration of Orphan Medical products as well as shaping a favorable regulatory environment for orphans. Throughout her career, Dr. Zimmerman has been directly involved in multiple regulatory approvals across the globe and most recently Strensiq approval in 2015 in Japan, Europe and the U.S. Dr. Zimmerman received her Pharm.D. from University Louis Pasteur in Strasbourg (France).